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Abstract
Background: Success rates of assisted reproductive techniques (ART) are approximately 30%, with the most important
limiting factor being embryo implantation. Mechanical endometrial injury, also called ‘scratching’, has been proposed to
positively affect the chance of implantation after embryo transfer, but the currently available evidence is not yet conclusive.
The primary aim of this study is to determine the effect of endometrial scratching prior to a second fresh in vitro
fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycle on live birth rates in women with a failed first IVF/ICSI cycle.
Method: Multicenter randomized controlled trial in Dutch academic and non-academic hospitals. A total of 900 women
will be included of whom half will undergo an endometrial scratch in the luteal phase of the cycle prior to controlled
ovarian hyperstimulation using an endometrial biopsy catheter. The primary endpoint is the live birth rate after the 2nd
fresh IVF/ICSI cycle. Secondary endpoints are costs, cumulative live birth rate (after the full 2nd IVF/ICSI cycle and over
12 months of follow-up); clinical and ongoing pregnancy rate; multiple pregnancy rate; miscarriage rate and endometrial
tissue parameters associated with implantation failure.
Discussion: Multiple studies have been performed to investigate the effect of endometrial scratching on live birth rates
in women undergoing IVF/ICSI cycles. Due to heterogeneity in both the method and population being scratched, it
remains unclear which group of women will benefit from the procedure. The SCRaTCH trial proposed here aims to
investigate the effect of endometrial scratching prior to controlled ovarian hyperstimulation in a large group of women
undergoing a second IVF/ICSI cycle.
Trial registration: NTR 5342, registered July 31st, 2015.
Protocol version: Version 4.10, January 4th, 2017.
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Background
In 2005, the combined number of assisted reproductive
technique (ART) cycles in the USA, Australia, New
Zealand and Europe was more than 600 000, and in
2002 the estimated global number of started ART cycles
was 1 million [1]. In-vitro fertilization (IVF) and intra-
cytoplasmic sperm injection (ICSI) are the most com-
mon ART treatments. Despite advances that have been
made since the introduction of these techniques, im-
plantation of the embryo is still the most important
rate-limiting step: even high quality embryos frequently
fail to implant resulting in an implantation rate of ap-
proximately 25–30% per transferred embryo [2, 3].
Over the past decade, intentional injury to the endo-
metrial lining, also called “scratching”, has been pro-
posed as a method to improve implantation. The
foundation for these findings was laid early in the 20th
century, when Loeb et al. showed that in guinea pigs,
mechanical irritation of the endometrium at 2–9 days
after ovulation led to decidualization [4]. Barash et al.
[5] were the first to test the hypothesis that endometrial
injury in the natural cycle prior to controlled ovarian
hyperstimulation (COH) could increase the chance of
pregnancy, and found a two-fold increase in live birth
rate after multiple endometrial scratches compared to
no scratch. Since then, multiple study groups have investi-
gated the effect of endometrial scratching on implantation
rate with differences in population, device used (a soft
plastic endometrial biopsy catheter, Karman cannula or
Novak curette), timing (luteal or follicular phase), and
frequency [6–16]. Several hypotheses supporting the
positive effect of scratching on pregnancy rates have
been proposed but the exact mechanism remains un-
clear [17, 18]. A Cochrane review by Nastri et al. sug-
gests that for women undergoing ART, an endometrial
scratch in the month prior to COH improves the
chance of achieving a clinical pregnancy and live birth
in women with two or more previously failed embryo
transfers, but the evidence is of moderate quality at best
[17]. Another review on endometrial injury in women
undergoing ART could not perform a meta-analysis due
to significant clinical heterogeneity, and could therefore
not draw conclusions on the effectiveness of scratching
[18]. This stresses the need for large randomized con-
trolled trials on specific subgroups of subfertile couples.
The study introduced here aims to determine if endomet-
rial scratching in the cycle prior to COH in women with
one previously failed full IVF/ICSI cycle increases the
chance of live birth. It also aims to evaluate if this leads to
a decrease in the number of ART cycles and costs needed
to achieve a live birth. Furthermore, the study contains an
embedded study that aims to determine characteristics,
such as RNA profiles, of the endometrial lining that are
associated with implantation failure.
Method
Study objective & design
The aim of this study is to evaluate whether endometrial
scratching in the cycle prior to a second ART cycle leads
to a higher number of ongoing pregnancies with live births
as compared to no scratching, in women with a failed first
IVF/ICSI cycle. While other studies have chosen to study
women with recurrent implantation failure (RIF), usually
defined as implantation failure of three high-quality embryo
transfers, this study focuses on an intervention after one
failed IVF/ICSI cycle in order to augment the efficacy of
ART in an early phase of treatment. Moreover, the study
seeks to determine endometrial characteristics such as
RNA profiles correlating with (un)successful implantation.
The SCRaTCH study is a Dutch multicenter – both
academic and non-academic – randomized controlled
trial (RCT) coordinated from the University Medical
Center Utrecht, and will be performed within the Dutch
Consortium for Healthcare Evaluation and Research in
Obstetrics and Gynecology. A prospective cohort study
is embedded within the RCT and will be performed in 6
dedicated centers, in which the endometrial biopsy will
be banked after which characteristics associated with
(un)successful implantation will be determined. The pri-
mary endpoint is live birth rate after the second fresh
ART cycle. Secondary endpoints include cumulative on-
going pregnancy and live birth rate after the full second
ART cycle; cumulative ongoing pregnancy and live birth
rate after 12 months of follow-up; biochemical, clinical,
ongoing and multiple pregnancy rate; implantation rate;
miscarriage rate; time to pregnancy; costs; and endo-
metrial tissue parameters associated with implant-
ation failure, such as endometrial gene expression
profiles.
In the RCT, a total of 900 women will be included of
which approximately 200 will also be included in the
embedded study. Based on previous studies, the difference
in live birth rate after the second ART cycle is estimated to
be at least 9% between the patients with and without endo-
metrial scratch (39% vs. 30%). The number of patients
needed to have 80% power (with two-tailed alpha of 0.05)
to detect such a difference is 450 per study arm, resulting
in 900 patients in total. This number takes into account an
estimated dropout rate of 3% and is calculated without
continuity correction in STATA.
Monitoring will be performed by the Data and Safety
Monitoring Board (DSMB) of the Dutch Consortium for
Healthcare Evaluation and Research in Obstetrics and
Gynecology – NVOG 2.0. The DSMB has several roles,
including monitoring for evidence of treatment harm,
such as serious adverse events, and advising on continu-
ation or terminating of the trial. Interim analyses have
not been planned. In case of injury as a consequence of
study participation, compensation is assured through a
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liability insurance of the coordinating center (the sponsor).
The DSMB charter is shown in the appendix.
Study population
Women planning a second full IVF/ICSI cycle with a
regular indication for IVF/ICSI and a failed implantation
after one full fresh ART cycle are eligible. At least one
embryo (either fresh or frozen/thaw) must have been
transferred during the first IVF/ICSI cycle. Failed im-
plantation is defined as the absence of a clinical preg-
nancy in the full first cycle. In case of total fertilization
failure after the first IVF/ICSI cycle, and at least one
embryo transfer during the second IVF/ICSI cycle, patients
are also eligible before the start of their third IVF/ICSI
cycle. Inclusion criteria are female age between 18 and
44 years, with primary or secondary infertility, and a normal
transvaginal ultrasound defined as no visible intracavitary
pathology (e.g. polyps or intramural myomas with impres-
sion of the uterine cavity). Exclusion criteria are a history of
lower abdominal or pelvic infection, a higher chance of
intra-abdominal infection due to intestinal surgery, endo-
metriosis grade 3 and 4, previous caesarean section with
niche formation, the presence of untreated unilateral or
bilateral hydrosalpinx, previous endometrial scratching,
meno-metrorrhagia, and untreated endocrine abnormal-
ities. Patients undergoing oocyte donation cycles or preim-
plantation genetic diagnosis (PGD) are also excluded since
oocyte donation patients have a different etiology for infer-
tility than recurrent implantation failure, and PGD patients
usually are not infertile.
Recruitment, consent and randomization
Eligible women will receive oral and written information
from their gynecologist or fertility physician, and will be
invited for additional counseling by the investigator or
research nurse to allow the women to make an informed
decision on participating in the study. After signing a
written informed consent the patient is randomly allo-
cated to either the scratch procedure before the start of
the second IVF/ICSI cycle or to direct start of the second
IVF/ICSI cycle. Randomization is performed by a web-
based randomization program using random blocks with
block size varying from two to four. Due to the nature of
the intervention, patients and physicians are not blinded
for this study, nor will a placebo intervention be per-
formed. As the primary outcome is a ‘hard endpoint’ we
do not expect results to be influenced by the fact that
there is no allocation concealment.
Study procedure
In the intervention group, an endometrial scratch will be
performed once during the luteal phase of the cycle prior
to controlled ovarian hyperstimulation. The scratch will be
done 10 to 5 days prior to the expected menstruation in
the overall group, and 5-8 days after a positive urine ovula-
tion test for the subgroup participating in the embedded
study. A dedicated gynecologist or fertility physician, with a
maximum of 3 dedicated physicians per center, will per-
form the scratch. Women are instructed not to be pregnant
during the procedure. After disinfection of the uterine
cervix with betadine, an endometrial biopsy catheter will be
introduced through the cervix up to the uterine fundus.
The piston will be drawn back to the end of the biopsy
cannula, after which the examiner slowly retracts the
catheter while rotating over several ranges of 360° during
1–2 min. For the subgroup of whom the endometrial
biopsy will be stored, the protocol differs slightly. Firstly,
during the procedure a sterile gown, gloves and cap will
be worn in order to prevent RNA contamination. Sec-
ondly, disinfection will not be performed with betadine
but with sterile water because betadine could affect the
outcomes of RNA analysis. Directly after the procedure,
sterile gloves will be changed for new gloves in order to
prevent RNA contamination. The endometrial tissue will
be divided into three equal parts, put into Tissue Sampling
Storage Tubes (3 ml, Cat. No. 68–4000-00, Fluid X) and
snap frozen in liquid nitrogen. Time from taking the
biopsy to snap freezing the tissue is maximally 3 min. Sub-
sequently, tissue will be stored in freezers at -80 °C.
Immediately after taking the biopsy, the patient will be
asked to indicate the degree of discomfort on a visual
analog scale. One week after the procedure the patient
will be contacted to evaluate if any complications oc-
curred. All patients, both the intervention and control
group, will receive standard ART therapy consisting of a
short antagonist, short agonist, or long agonist protocol.
GnRH agonists can be used in the overall group, but
within the embedded study subpopulation GnRH agonists
are started after the scratch has been performed. An over-
view of the phases of the study is shown in Fig. 1.
ART, assisted reproductive techniques. IVF, in vitro
fertilization. ICSI, intracytoplasmic sperm injection. EGP,
endometrial genomic profile. *Timing applies to the over-
all study. In the embedded study the endometrial scratch
is performed on day 5–8 after the LH surge measured by
urine ovulation tests. The boxes in pink apply to the
embedded study.
Follow-up
Each center registers if a patient has conceived during
the 12 months after randomization. When a woman has
become pregnant, she will undergo ultrasounds at ap-
proximately 7 weeks and 10–12 weeks of gestation, after
which she will continue prenatal care at the midwife
or the gynecologist. At the due date, a questionnaire
will be sent with questions about the course of the
pregnancy and the delivery. If a woman has not con-
ceived within 12 months, information on further
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fertility treatment will be extracted from the electronic
patient file. Missing information will be completed by
telephone contact with the participant, using a struc-
tured questionnaire.
Statistical analysis
Anonymized data will be collected in a web based regis-
tration system. Database cleaning will be carried out by
internal consistency checks and identification of data-
base entries outside expected ranges. Analysis will pri-
marily be according to intention-to-treat. If many
women in the intervention group end up not having
the scratch procedure, a per protocol analysis may also
be performed to clarify whether the magnitude of effect
may have been underestimated.
SPSS and Excel will be used to perform the statis-
tical analysis. The outcome variables of the primary
and secondary endpoints (except the costs, of which
analysis is described below) will be compared between
the treatment arms, and expressed as relative risk with
95% confidence interval. A probability (p) less than
0.05 will be considered to be significant.
Fig. 1 Study flowchart
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Cost-effectiveness analysis
The economic evaluation is designed from both a health-
care and a societal perspective. A cost-effectiveness ana-
lysis covering a period of 12 months will be performed
parallel to the clinical trial. This cost-effectiveness analysis
will be based on live birth rate and average costs per
patient. Impact on patient’s life will be expressed in
quality-adjusted life years (QALY), and will be estimated
based on other studies performed within the Dutch
Consortium for Healthcare Evaluation and Research in
Obstetrics and Gynecology – NVOG 2.0. A decision
model will be used to evaluate the optimal strategy, taking
into account the time to pregnancy, direct and indirect
costs on the one hand, and estimated QALY on the other
hand. Moreover, the incremental cost-effectiveness ratio
(ICER) and long term costs such as delivery and perinatal
costs will be determined. Sensitivity analysis will define
robustness of the results.
Discussion
Intentional endometrial injury is frequently being per-
formed in women undergoing IVF without conclusive
scientific evidence on its beneficial effects. For example,
across Australia, New Zealand and the UK it is advised
to patients undergoing IVF by 83% of the clinicians
working in a fertility clinic [19]. Multiple studies have
been performed to investigate the effect of endometrial
scratching in women undergoing ART cycles, but the
method of scratching, the population being scratched
and the study quality varies widely [17, 18]. Due to this
heterogeneity in design and variability in quality, it re-
mains unclear for whom this extra treatment could be
beneficial, and for whom it is redundant [18]. This
stresses the need for large randomized controlled trials
in specific subpopulations and for an individual patient
data analysis to reduce heterogeneity. The current study
will evaluate the effect of endometrial scratching on live
birth after the second fresh ART cycle in women with a
failed first full IVF/ICSI cycle. Although this subgroup is
rather well-specified, heterogeneity still exists: number
of other fertility treatments such as intra-uterine insem-
ination prior to IVF could differ, and women may have
had a different number of frozen/thaw embryo transfers.
However, from an intention-to-treat point of view, this
study has selected a clear population; namely a popula-
tion that has shown to have had at least one failed
implantation. Although frequently the term ‘implant-
ation failure’ is used for women with implantation failure
of at least three high-quality embryo transfers [20, 21],
this study focuses on maximizing the effectiveness of
ART earlier during the process, keeping in mind both
patient burden and healthcare costs. In addition, Koot et
al. have shown that endometrial genomic profiles (EGP)
show different characteristics in women with and
without repeated implantation failure (RIF) [22]. The
current study seeks to identify if this EGP predicts the
chance of conception within 1 year of IVF treatment.
Also, identifying an EGP that is related to endometrial
failure could help clinicians in counselling patients and
it opens possibilities for further research into endometrial
receptivity. Another point of discussion is whether the use
of povidone-iodine during the endometrial scratch could
affect implantation. To our knowledge, no RCTs have
been performed investigating the effect of cervical disin-
fection with povidone-iodine 3–4 weeks prior to embryo
transfer on the endometrial lining or on embryo implant-
ation. Therefore, it was decided that in this trial, the bene-
fit of reducing the risk of infection outweighs the risk of a
possible negative effect of povidone-iodine on embryo im-
plantation. Still, for the subgroup of the embedded study
povidone-iodine disinfection is not used because this
could influence the outcome of RNA profile analysis. In
conclusion, the SCRaTCH study is a large randomized
controlled trial and aims to elucidate if an endometrial
scratch in the luteal phase prior to COH improves the
chance of a live birth for patients with a failed first IVF/
ICSI cycle.
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